Research programme: cancer therapeutics - RESprotectAlternative Names: RP-656; RP-701; RP-885
Latest Information Update: 09 Aug 2010
At a glance
- Originator RESprotect
- Class Small molecules
- Mechanism of Action Apoptosis stimulants; Genetic transcription inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 06 Aug 2010 Preclinical trials in Cancer in Germany (PO)